Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Bode

Showing results (21-30 of 600) with videos related to

Pageof 60
Sort By:
Current Opinion in Cardiology|April 28, 2009
New antithrombotic agents in acute coronary syndromesMartin Moser, Christoph Bode
Seminars in Hematology|May 28, 2014
Direct oral anticoagulants in acute coronary syndromeIngo Ahrens, Christoph Bode
Future Cardiology|August 9, 2012
Rivaroxaban for stroke prevention in atrial fibrillation and secondary prevention in patients with a recent acute coronary syndromeIngo Ahrens, Christoph Bode
Hamostaseologie|March 29, 2018
59th Annual Congress of the Gesellschaft für Thrombose- und Hämostaseforschung e. VRüdiger E Scharf, Christoph Bode
Journal of Cardiovascular Medicine (Hagerstown, Md.)|July 1, 2009
The need for new oral anticoagulants in clinical practice: an introductionChristoph Bode, Freek Wa Verheugt
Journal of Thrombosis and Thrombolysis|March 9, 2021
Medical publishing during the COVID-19 pandemic: then and nowRichard C Becker, Christoph Bode
Expert Review of Cardiovascular Therapy|September 11, 2010
Clopidogrel in acute coronary syndrome: implications of recent study findingsDaniel Duerschmied, Christoph Bode, Martin Moser
Herz|April 2, 2004
Drug-eluting stents for in-stent restenosis and acute myocardial infarction: present data from nonrandomized studiesJoachim Schofer, Christoph Bode, Sigmund Silber
Therapeutics and Clinical Risk Management|September 9, 2015
Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosisPhilipp Diehl, Christoph Bode, Daniel Duerschmied
Seminars in Thrombosis and Hemostasis|November 7, 2002
Hirudin in acute coronary syndromesAndreas van de Loo, Christoph Bode
Pageof 60

Showing results (21-30 of 600) with videos related to

Sort By:
Pageof 60
Current Opinion in Cardiology|April 28, 2009
New antithrombotic agents in acute coronary syndromesMartin Moser, Christoph Bode
Seminars in Hematology|May 28, 2014
Direct oral anticoagulants in acute coronary syndromeIngo Ahrens, Christoph Bode
Future Cardiology|August 9, 2012
Rivaroxaban for stroke prevention in atrial fibrillation and secondary prevention in patients with a recent acute coronary syndromeIngo Ahrens, Christoph Bode
Hamostaseologie|March 29, 2018
59th Annual Congress of the Gesellschaft für Thrombose- und Hämostaseforschung e. VRüdiger E Scharf, Christoph Bode
Journal of Cardiovascular Medicine (Hagerstown, Md.)|July 1, 2009
The need for new oral anticoagulants in clinical practice: an introductionChristoph Bode, Freek Wa Verheugt
Journal of Thrombosis and Thrombolysis|March 9, 2021
Medical publishing during the COVID-19 pandemic: then and nowRichard C Becker, Christoph Bode
Expert Review of Cardiovascular Therapy|September 11, 2010
Clopidogrel in acute coronary syndrome: implications of recent study findingsDaniel Duerschmied, Christoph Bode, Martin Moser
Herz|April 2, 2004
Drug-eluting stents for in-stent restenosis and acute myocardial infarction: present data from nonrandomized studiesJoachim Schofer, Christoph Bode, Sigmund Silber
Therapeutics and Clinical Risk Management|September 9, 2015
Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosisPhilipp Diehl, Christoph Bode, Daniel Duerschmied
Seminars in Thrombosis and Hemostasis|November 7, 2002
Hirudin in acute coronary syndromesAndreas van de Loo, Christoph Bode
Pageof 60